Navigation Links
According to Surveyed EU5 Oncologists, Zelboraf Captures 50 Percent Patient Share of the First-Line BRAF-Mutation Positive Malignant Melanoma Population
Date:12/2/2013

EXTON, Pa., Dec. 2, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that, according to oncologists surveyed in Q3 2013, Roche/Genentech/Daiichi Sankyo/Chugai's Zelboraf, on average, garners 50 percent patient share across the EU5, in the first-line BRAF-mutation positive setting. In the BRAF-wild-type (BRAF-negative) population, treatment is still dominated by the alkylating agent, dacarbazine (generics). Surveyed oncologists also report that Bristol-Myers Squibb's Yervoy holds, on average, nearly one-third of patient share in second-line BRAF-mutation-positive setting, according to surveyed EU5 oncologists; however, penetration of Yervoy across the EU5 is variable. The vast majority of surveyed respondents cite moderate to high satisfaction with Yervoy and Zelboraf, and surveyed oncologists anticipate a significant increase in first-line prescribing of these agents in BRAF-wild-type and BRAF-mutation-positive malignant melanoma, within the next six months.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36805LOGO )

According to the data published in the TreatmentTrends® Malignant Melanoma (EU) Q4 2013 report, surveyed EU5 medical oncologists and dermatologists, with the exception of respondents from Spain, report that low-dose Intron A (Merck) garners more patient share than high-dose Intron A as adjuvant treatment for resectable malignant melanoma. High-dose Intron A has significant perceived advantage over low-dose Intron A with respect to efficacy attributes. Conversely, low-dose Intron A has a perceived advantage on safety and tolerability and outperforms high-dose Intron A on experience/familiarity, cost to healthcare system and ease of administration. 

"Physicians surveyed in 2013 report significantly higher rates of BRAF-mutation screening in their unresectable and metastatic patients compared with survey findings from 2012; however, we still see variation in BRAF-screening rates across the EU5," said Decision Resources Group Senior Business Insights Analyst Karen Pomeranz, M.Sc., Ph.D. "Surveyed oncologists expect BRAF-screening to increase in almost all stages of disease within the next six months, whereas surveyed dermatologists expect screening rates to significantly increase in only their earlier-stage resectable patients."

TreatmentTrends® Malignant Melanoma (EU) is a syndicated report designed to provide a view of the current and future management of malignant melanoma based on primary research fielded with 252 medical oncologists in Europe (France, Germany, Italy, Spain, United Kingdom) and 68 dermatologists (Germany only). The report evaluates treatment and diagnosis patterns of the disease and physician opinions on possible future therapy options. BioTrends Oncology is also covering the launch of Tafinlar and Mekinist through its LaunchTrends® studies.

About BioTrends Research Group
BioTrends Research Group provides syndicated and custom primary market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. For information on BioTrends publications and research capabilities, please visit www.bio-trends.com. BioTrends is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks of their respective holders.

For more information, contact:

Decision Resources Group 
Christopher Comfort 
781-993-2597 
ccomfort@dresources.com


'/>"/>
SOURCE BioTrends Research Group
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. According to Surveyed U.S. Oncologists, Zelboraf is the Patient Share Leader in First-Line BRAF-Mutation Positive Malignant Melanoma
2. mHealth market is Expected to Reach $58.8 Billion Globally by 2020 According to Allied Market Research Projections
3. More than a Third of Chronic Kidney Disease-Non-Dialysis Patients are Likely Candidates for FG-4592/ASP1517, According to Surveyed EU5 Nephrologists
4. According to Surveyed U.S. Oncologists, Zytiga is the Patient-Share Leader in First-Line Metastatic Castrate-Resistant Prostate Cancer
5. In Terms of Effect on Overall Survival, Current and Emerging Therapies Have No Advantage Over Avastin/FOLFIRI in the Treatment of Second-Line Metastatic Colorectal Cancer, According to Clinical Data and Thought Leader Opinion
6. Rising Drug Resistance is Driving Early-Line Use of Powerful Antibiotics Such as Carbapenems for Gram-Negative Infections, According to Surveyed EU5 Physicians
7. Annual Healthcare Cost for a Typical American Family is $22,030 According to 2013 Milliman Medical Index
8. Type 2 Diabetes Control Worsening, According To Study Of Patients On Commercial Insurance
9. Fewer Venture Capital Dollars Invested Into Life Sciences Companies In Q1 2013, According To The MoneyTree Report
10. Food Recalls Driven by Companies Issuing Multiple Recalls in the First Quarter of 2013, According to Latest ExpertRECALL Index
11. Nearly 8 Million Healthcare Personnel Come in Contact with Chemotherapy Drugs, According to CDC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... -- CSI Specialty Group (CSI) expanded its specialty pharmacy ... Pharmacy Podcast. A free, weekly show, the Specialty Pharmacy ... discussion and context amongst specialty pharmacy peers and professionals. ... The Specialty Pharmacy Podcast, hosted by industry leader ... DiMascio, CHE, CMCE, CPC, is available for streaming and/or ...
(Date:2/10/2016)... and SAN DIEGO , Feb. 10, ... global leader in viral gene therapy manufacturing, and Renova™ ... congestive heart failure and other chronic diseases, have entered ... manufacturing process and produce cGMP-grade RT-100 (Ad5.hAC6) Drug Product ... --> --> This relationship ...
(Date:2/10/2016)... -- Urologix, the market leader for in-office minimally invasive ... (BPH), announces new private ownership and is operating as ... industry veteran of more than 20 years, has been ... Plymouth, Minn. The company,s two ... RF Therapy, will continue to be broadly available and ...
Breaking Medicine Technology:
(Date:2/10/2016)... ... February 10, 2016 , ... As part of its ongoing series of ... Each webinar features a dynamic expert and thoughtful presentation to give attendees a ... facilities. Both events are free to attend, but registration is required. ...
(Date:2/10/2016)... ... February 10, 2016 , ... Emergency rooms provide emergency care to stabilize ... can leave patients with dental emergencies at risk of losing a tooth or their ... care. , Common dental emergencies include:, , Avulsed or ...
(Date:2/10/2016)... ... February 10, 2016 , ... Intalere’s 2016 Executive ... than 200 of the country’s top healthcare executives to share insights on transformational ... of the Forum is the provider-centric perspective, experience, expertise and strategy shared by ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... award winner and inspirational speaker Jan Fox will serve as keynote speaker at ... will provide participants with tools to more effectively communicate with their own organizational ...
(Date:2/10/2016)... ... February 10, 2016 , ... Everseat has joined ... readily available to physicians. The integration will enable Allscripts users to post open ... Everseat’s free mobile app. , The partnership gives Everseat substantial added power to ...
Breaking Medicine News(10 mins):